CAR-T 序贯造血干细胞移植治疗复发/难治血液系统恶性肿瘤的研究进展与临床实践
郭嘉仪 ,贺小圆 ,赵明峰 *
作者信息
- 天津市第一中心医院血液科,天津市血栓与止血研究所,天津 300192
* 通信作者
摘要
嵌合抗原受体 T 细胞疗法(CAR-T)在复发/ 难治(R/ R)血液系统恶性肿瘤中仍存在较高复发率,而造血干细胞移植(HSCT)对高肿瘤负荷患者疗效有限。 针对上述临床核心问题,本文围绕“CAR-T 先期减瘤联合 HSCT 巩固重建”这一序贯治疗策略,系统梳理国内外相关临床研究进展,综合分析该模式在不同病种中的疗效、协同作用机制,以及移植时机、预处理方案等关键环节的优化策略。 既往结果表明,CAR-T 序贯HSCT 通过阶梯式肿瘤清除、双向免疫重塑与技术优势互补,可实现协同治疗效果;我国建立的原创序贯方案,为存在难治靶点及儿童高危患者提供了新的根治路径,具有重要的临床价值与个体化指导意义。
Research progress and clinical practice of CAR-T sequential hematopoietic stem cell transplantation in the treatment of relapsed/refractory hematological malignancies
Jiayi GUO , Xiaoyuan HE , Mingfeng ZHAO *
Author Information
- Department of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin 300192, China
*Corresponding author
Abstract
Chimeric antigen receptor T-cell therapy (CAR-T) still exhibits a high relapse rate in relapsed / refractory (R/ R) hematologic malignancies, while hematopoietic stem cell transplantation (HSCT) has limited efficacy for patients with high tumor burden. Addressing these core clinical challenges, this article systematically reviews domestic and international clinical research progress on the sequential treatment strategy of " CAR-T upfront tumor reduction combined with HSCT consolidation and reconstruction. " It comprehensively analyzes the efficacy, synergistic mechanisms, and optimization strategies for key aspects such as transplantation timing and conditioning regimens across different disease types. Previous studies have shown that sequential CAR-T followed by HSCT achieves synergistic therapeutic effects through stepwise tumor clearance, bidirectional immune remodeling, and complementary technical advantages. The original sequential protocol developed in China provides a novel curative pathway for patients with refractory targets and high-risk pediatric cases, demonstrating significant clinical value and personalized guidance potential.
